Macular Degeneration Agents Need Randomized Trials, Medicare Panel Says

Manufacturers developing treatments for age-related macular degeneration (AMD) should conduct randomized, controlled trials, the Centers for Medicare & Medicaid Services' Medicare Coverage Advisory Committee recommended at a Nov. 29 meeting in Baltimore